Fibrocell to Report Third Quarter 2015 Financial and Operating Results, and Host Conference Call and Webcast on Thursday, November 5, 2015

EXTON, Pa., Oct. 29, 2015 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, will report third quarter 2015 results on Thursday, November 5, 2015, before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. ET on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks.

To participate on the live call, please dial 855-877-0343 (domestic) or +1-678-509-8772 (international), and provide the conference code 59105396 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell’s website at www.fibrocellscience.com/investors/events-and-presentations/, and will be archived there for 30 days following the call. Please visit Fibrocell’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Fibrocell Science, Inc.

Fibrocell is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin diseases using gene-modified autologous fibroblasts. Fibrocell is in pre-clinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy product candidate, for the treatment of linear scleroderma. For more information, visit www.fibrocell.com.

CONTACT: Investor & Media Relations Contact:
Karen Casey
Fibrocell Science
+1 (484) 713-6133
kcasey@fibrocell.com